🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

17 results for “Galera Therapeutics” Clear

  1. GC4419 90mg

    Galera Therapeutics

    Oral Mucositis

    phase 3 small molecule completed

    1 trial

  2. Drug GC4711

    Galera Therapeutics

    SBRT

    phase 2 small molecule terminated

    1 trial

  3. Drug: GC4419

    Galera Therapeutics

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  4. GC4419

    Galera Therapeutics

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  5. GC4419

    Galera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  6. GC4419 (avasopasem manganese)

    Galera Therapeutics

    Esophagitis

    phase 2 small molecule terminated

    1 trial

  7. GC4711 +SBRT

    Galera Therapeutics

    SBRT

    phase 2 small molecule terminated

    1 trial

  8. Low Dose GC4419: 30mg/day

    Galera Therapeutics

    Radiation Induced Oral Mucositis

    phase 2 small molecule completed

    1 trial

  9. Dextromethorphan HBr

    Galera Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  10. GC4419

    Galera Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. GC4419

    Galera Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  12. GC4419

    Galera Therapeutics

    Squamous Cell Carcinoma of the Oral Cavity

    phase 1 small molecule completed

    1 trial

  13. GC4419 IV

    Galera Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  14. GC4702 dry powder

    Galera Therapeutics

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  15. GC4711 30 mg IV

    Galera Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. GC4711 30mg

    Galera Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  17. GC4711 Oral Capsule G-101

    Galera Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources